Alt_Fuel
Nov 20, 5:56 PM
$VSTM
$ERAS
$RVMD
KRAS at Triple Meeting:
Erasca wants to one-up RevMed,
while Alterome tries a different approach
Erasca presented updated Phase 1 data
on its pan-RAS molecular glue ERAS-0015
aiming to differentiate from Revolution Medicines (RevMed),
while Alterome shared early data on its distinct KRAS-selective pan-mutant (ON/OFF) inhibitor ALTA3263
at the 38th EORTC-NCI-AACR “Triple” Meeting in Barcelona
( approx. November 20, 2026).
Erasca (ERAS-0015) –
Seeking to one-up RevMed
Erasca positioned ERAS-0015 (a pan-RAS molecular glue,
similar in mechanism to RevMed’s daraxonrasib/Rasonque)
as potentially more potent and better tolerated.
Updated U.S. Phase 1 AURORAS-1 monotherapy data
at the 32 mg once-daily dose
(pharmacologically active range ~16–32 mg) included:
LINK -
https://grok.com/c/e1d8e535-fbab-4c44-890a-94ed32795e7f?rid=357fd6b9-5f71-43af-b503-9ad383c6931f
1 replies